Fatty Acid Oxidation Disorder Market Size

  • Report ID: 5403
  • Published Date: Nov 27, 2023
  • Report Format: PDF, PPT

Fatty Acid Oxidation Disorder Market Size

Fatty Acid Oxidation Disorder Market size is anticipated to reach USD 20 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of fatty acid oxidation disorder was over USD 10 Billion. The integration of telehealth services is one of the main growth drivers fueling the market. Telehealth can address the challenge of geographical disparities in access to specialized healthcare for individuals with FAODs. Patients residing in remote or underserved areas often face difficulties in accessing expert clinicians and metabolic disorder centers. By integrating telehealth services, healthcare providers can extend their reach to a broader patient population, ensuring timely consultations and follow-ups. According to a study, the use of telehealth services for chronic disease management led to a 25% reduction in hospitalizations and a 19% reduction in emergency department visits, emphasizing the positive impact on healthcare utilization.

Fatty acid oxidation disorders (FAODs) are a group of rare genetic metabolic disorders characterized by the body's inability to break down certain fats and convert them into energy. This results in a buildup of fatty acids in various tissues and organs, leading to a range of symptoms and complications. Supportive regulatory frameworks that facilitate the development and approval of treatments for rare diseases, including FAODs, can contribute to the growth of the market.


Fatty Acid Oxidation Disorder Market Overview

Browse Key Market Insights with Data Illustration:


Author Credits:  Smruti Ranjan, Rajrani Baghel


  • Report ID: 5403
  • Published Date: Nov 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of fatty acid oxidation disorder is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market Ultragenyx Pharmaceutical Inc., Recordati Rare Diseases Inc., Retrophin, Inc., Amicus Therapeutics, Inc., Aeglea BioTherapeutics, Inc., Zogenix, Inc., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying